SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is seeing renewed interest as the community rallies behind anticipated network upgrades, burn initiatives, and a shared long-term belief in a potential reversal. Traders are actively discussing the token's low entry point and perceived recovery potential, while comparing its resilience to broader market movements.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is drawing significant attention as investors react to a combination of institutional staking growth and anticipation surrounding potential regulatory developments. The community is actively debating the coin's long-term value, with active discussions focused on navigating market volatility while balancing sentiment between bullish price-appreciation narratives and concerns over liquidity shifts.

"What's Updog?" is a Community Led token.

UpDog

UpDog is generating significant buzz on social media as the Solana-based memecoin maintains steady community momentum and continues to feature prominently on trending lists. Enthusiasts are highlighting its long-term track record, locked liquidity, and ongoing community initiatives like poker nights to foster engagement and promote the project.

KAT is a defi token with governance-like mechanics for Katana.  It is designed to function as a lever for directing capital: users that lock KAT receive a voting version of KAT — vKAT — in return. vKAT underpins key aspects of the chain’s economy, providing rewards to those users that participate. these fee-based rewards function as an incentive for KAT holders to engage in cooperative, positive-sum behavior.

Katana

Katana is trending as traders debate its price action following a recent exchange listing, with the community closely tracking the project's new vKAT tokenomics and ve-style accrual system. While some investors view the asset as a high-potential DeFi utility play, others are expressing caution amidst volatile market movements and discussions regarding future migration plans.

DIEM transforms AI compute from a service you rent into an onchain asset you own: tokenized intelligence. Each Diem token represents $1 per day of Venice API capacity that never expires and never changes value.  DIEM are ERC20 tokens on Base and can be transferred, traded, and staked. DIEM can only be minted by locking staked VVV (sVVV), making DIEM and VVV a foundational assets for onchain AI. Tokenizing intelligence with DIEM creates new possibilities:  Developers/agents: 1 DIEM = $1/day Venice API access, forever VVV holders: Monetize unused compute as DIEM → earn yield → buy back later to unlock VVV Apps: Fixed AI costs, guaranteed capacity, no variable API bills Onchain economy: Agents own their intelligence, DeFi collateralizes compute  Minting DIEM with VVV creates a brand-new onchain building block for AI – programmable, composable compute

Diem

Diem is seeing heightened activity following its listing on Coinbase and ongoing discussions regarding its minting relationship with VVV. Market participants are actively debating the trade-offs between staking strategies and direct token accumulation as the ecosystem scales.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin remains a highly polarized asset on social media, with investors debating its long-term potential amid frustrations over stagnant price action and minimal communication from leadership. While some community members continue to accumulate aggressively, viewing current levels as a strategic buying opportunity for future cycles, others express deep skepticism and frustration regarding its performance relative to the broader crypto market.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

The community surrounding $UPDOG is actively highlighting the project's longevity on Solana and its presence on the Jupiter strict list, encouraging users to swap via JUP. Traders are also discussing broader market sentiment and utilizing JUP's lending features, despite some community frustration regarding exchange volatility and platform performance.

Magnachip Semiconductor Corp. engages in the design and manufacture of analog and mixed-signal platform solutions for communications, Internet of Things (IoT), consumer, computing, industrial, and automotive applications. Its products include MOSFETs, IGBTs, AC-DC/DC-DC converters, light-emitting diode (LED) drivers, regulators, power management integrated circuits (PMICs), and industrial applications such as power suppliers, e-bikes, photovoltaic inverters, LED lighting, and motor drives. The company was founded on November 26, 2003 and is headquartered in Cheongju-si, South Korea.

MagnaChip Semiconductor Corp

MagnaChip Semiconductor is currently a focal point for investors due to its attractive valuation and active share buyback program, which recently saw an expansion to $87.5 million. The community is actively debating the likelihood of a strategic buyout or merger, particularly with persistent rumors surrounding potential interest from South Korean conglomerates.

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Relay Therapeutics Inc

Relay Therapeutics is currently trending as institutional investors and the community weigh the potential for a multi-billion dollar acquisition, driven by the presence of a board experienced in major pharmaceutical buyouts and an upcoming clinical data catalyst in May. Market participants are closely monitoring the high concentration of institutional ownership and a substantial short position, which is fueling intense speculation regarding a potential structural breakout or buyout offer from major industry players like Pfizer or Novartis.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is drawing significant attention as institutional inflows remain robust despite broader market volatility, with the community actively debating whether Bitcoin's resilience amid geopolitical tensions signals a decoupling from traditional risk assets. Traders are closely monitoring heavy options activity and institutional accumulation patterns, as many look for confirmation of a durable bottom.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>If the proposed bidding process is approved, interested parties can submit binding offers to acquire Clearside’s assets in whole or in part.</li><li>CEO George Lasezkay said that the company has “attractive assets,” including its SCS Injection Platform.&nbsp;</li><li>The company has also filed several motions to enable normal operations during the process, it said.&nbsp; &nbsp;</li></ul>Clearside Biomedical, Inc. (CLSD) said on Monday that it has filed a voluntary petition for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware.Shares of the company traded nearly 69% lower at the time of writing.<h2 class="st-heading-2">What Does The Company Intend?</h2>The biopharmaceutical company is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/24/3193383/0/en/Clearside-Biomedical-to-Pursue-Strategic-Sale-of-its-Business-Through-Voluntary-Chapter-11-Process.html">seeking</a> authorization to pursue an auction and sale process. If the proposed bidding process is approved, interested parties can submit binding offers to acquire Clearside’s assets in whole or in part."Our Board of Directors and management team have thoroughly assessed all of our strategic options and believe that this Chapter 11 structured process represents the best possible option for Clearside and its stakeholders,” said CEO George Lasezkay.Lasezkay also added that the company has “attractive assets,” including its SCS Injection Platform, which is a proven in-office, repeatable, non-surgical procedure for the targeted delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.The company’s CLS-AX clinical development program is also up for sale. CLS-AX is being developed for the treatment of serious back-of-the-eye diseases, including neovascular age-related macular degeneration (wet AMD) and diabetic retinopathy.The company has also filed several motions to enable normal operations during the process, it said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CLSD jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:587/60;" src="data:image/png;base64,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" width="587" height="60" alt="CLSD’s Sentiment Meter and Message Volume as of 11:21 a.m. ET on Nov. 24, 2025 | Source: Stocktwits"><figcaption>CLSD’s Sentiment Meter and Message Volume as of 11:21 a.m. ET on Nov. 24, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CLSD">CLSD stock</a> is down by 94% this year and by about 95% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/oscar-health-stock-soars-on-reports-of-two-year-obamacare-subsidy-extension/cL5bB5mREQ7">Oscar Health Stock Soars On Reports Of Two-Year Obamacare Subsidy Extension</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, the Clearside Biomedical logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CLSD Stock Plummets After Company Files For Bankruptcy Protection

The biopharmaceutical company is seeking authorization to pursue an auction and sale process.

Equity

The biopharmaceutical company is seeking authorization to pursue an auction and sale process.


Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates

Clearside Biomedical (CLSD) delivered earnings and revenue surprises of -70.15% and -23.57%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -4.86% and -18.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of -5.26% and +15.42%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates

ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of -11.76% and +35.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates

Clearside Biomedical (CLSD) delivered earnings and revenue surprises of +50.00% and +87.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates

Compugen (CGEN) delivered earnings and revenue surprises of -14.29% and -76.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know

Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

Clearside Biomedical, Inc. is a biopharmaceutical company that delivers therapies to the back of the eye through the suprachoroidal space. Its SCS microinjector enables a simple, repeatable, in-office procedure to deliver treatments directly to the macula, retina, or choroid, potentially helping to preserve and improve vision in patients with serious eye diseases. Its pipeline includes CLS-AX, an Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Current Price	$0.31
Prev Close	$0.31
Open	$0.34
Dividend Yield	N/A
50-Day Moving Average	$0.4829
Beta	0.48
Avg. Volume	21,234.09
PE Ratio	-0.06

52-Week High	$14.09
52-Week Low	$0.1101
Market Capitalization	$1.62M
EPS (Annual)	N/A
Price to Book	-0.03
Revenue Per Employee	N/A

CLSD
Clearside Biomedical Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CLSD News

CLSDClearside Biomedical Inc